홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

라니티딘

Ranisen

HCID 5039
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
66357-35-5
표준 SMILES
CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1
InChIKey
VMXUWOKSQNHOCA-UHFFFAOYSA-N
분자식
C13H22N4O3S
평균 분자량
314.41 g/mol
단동위원소 질량
314.14126175

개요

Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion. Ranitidine is often referred to as Zantac, and is available in various forms, including tablet, injection, and effervescent tablet preparations. The prevalence of GERD is thought to be 10-20% in western countries. Ranitidine has proven to be an effective treatment for relieving uncomfortable symptoms of gastric acid associated conditions and is therefore widely used in GERD and other gastric-acid related conditions.

이름 및 식별자

우선 이름
Ranisen
IUPAC
1-N'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine
현지명
라니티딘
영어명
Ranitidine
분자식
C13H22N4O3S
분자량
314.4

이름 및 동의어

AchedosDuractinIstomarMicrotidPtinolinQuicranRadinatRanidineRaniogasRanisenRaniterRanitiget
이름 더 보기
라니티딘RANITIDINE BASERanitidinTriggerRANITIDINE USPRNDU1cexTauralZantaeZanticSampep
RantacidRaticinaUlceraninUrantacVerlostVizerulWeichilinXanidine

데이터베이스 식별자

CAS
66357-35-5
PubChem CID
5039
DTXSID
DTXSID8045191
ChEMBL
CHEMBL1790041
UNII
884KT10YB7

물성

구조 계산 물성

XLogP
0.3
극성 표면적
112 Ų
수소 결합 공여자 수
2
수소 결합 수용자 수
7
회전 가능 결합 수
9
무거운 원자 수
21
형식 전하
0
복잡도
347

실험 및 물리화학적 성질

DrugsPharmaceuticals -> Antiulcer Drugs
LogP0.64
Solubilitysoluble in water
Dissociation Constants · 2건

8.31

8.2 and 2.7

Collision Cross Section169.0 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID8045191]

물리화학적 성질

녹는점
69 · 69-70°C
끓는 점
437.1 · 437.1±45.0 °C(Predicted)
밀도
1.184 · 1.184±0.06 g/cm3(Predicted)
저장 조건
4 °C · Desiccate at +4°C
용해도
2 O: · H2O: 1.8 mg/mL
산도 계수 (pKa)
2.19 · pKa 2.19±0.04 (Uncertain)
물리적 상태
고체
색상
갈색을 띤 노란색
수용성
24.7 mg/mL · 24.7mg/mL
안정성
흡습성
NIST
Ranitidine(66357-35-5)
EPA
1 · 1,1-Ethenediamine, N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro- (66357-35-5)

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

안전 데이터

wgk
2
rtecs
KM6557000
독성
LD50 oral in rat: > 5gm/kg
safety_code
22-24/25
유해 물질 데이터
66357-35-5(Hazardous Substances Data)

화학 및 산업

약리 정보

ATC CodeA02BA02
Protein BindingThe plasma protein binding of ranitidine is approximately 15%.
Pharmacodynamics · 1건

Ranitidine decreases the secretion of gastric acid stimulated by food and drugs. It also reduces the secretion of gastric acid in hypersecretory conditions such as Zollinger-Ellison syndrome. Marked improvements in the appearance of the esophageal tissues have been observed by endoscopic imaging after ranitidine therapy.

Mechanism of Action · 1건

After a meal, the hormone gastrin, produced by cells in the lining of the stomach, stimulates the release of histamine, which then binds to histamine H2 receptors, leading to the secretion of gastric acid. Ranitidine reduces the secretion of gastric acid by reversible binding to histamine (H2) receptors, which are found on gastric parietal cells. This process leads to the inhibition of histamine binding to this receptor, causing the reduction of gastric acid secretion. The relief of gastric-acid related symptoms can occur as soon as 60 minutes after administration of a single dose, and the effects can last from 4-10 hours, providing fast and effective symptomatic relief.

Biological Half-Life · 1건

The elimination half-life or ranitidine is about 2.5-3 hours. It may be longer after oral administration versus injection. The plasma half-life is longer for elderly patients population due to a decrease in renal function, and is measured at 3-4 hours.

Metabolism/Metabolites · 1건

The major metabolite in the urine is N-oxide, which represents less than 4% of the dose. Other metabolites of ranitidine include S-oxide (1%) and desmethyl ranitidine (1%). The feces contain the remainder of the excreted ranitidine dose. Liver dysfunction has been shown to cause small, but clinically insignificant, changes in various ranitidine pharmacokinetic parameters.

Absorption, Distribution and Excretion · 4건

Ranitidine is rapidly absorbed with peak concentrations reached within 1-3 hours after administration, and varying greatly among patients. Bioavailability is about 50%-60% due to hepatic metabolism. In a pharmacokinetic study of healthy males, the AUC 0-infinity was about 2,488.6 ng x h/mL and the median Tmax was 2.83 hours. Food or antacids have limited effects on absorption. One clinical study found that the administration of a potent antacid (150 mmol) in subjects in the fasted state led to decreased absorption of ranitidine.

This drug is mainly excreted in the urine but also excreted in the feces. About 30% of a single oral dose has been measured in the urine as unchanged drug within 24 hours of ingestion.

The volume of distribution is higher than body volume, and measures at approximately 1.4 L/kg. It concentrates in breast milk, but does not readily distribute into the cerebrospinal fluid.

Renal clearance is about 410 mL/min according to FDA prescribing information. Another resource mentions a plasma clearance of approximately 600 ml/min. Clearance is decreased in the elderly and those with impaired or hepatic renal function. It is recommended to decrease the dose of ranitidine by one-half in patients with renal impairment.

응용 분야 · 4건

개요Ranitidine, a H2-receptor agonist, caused contact dermatitis within the pharmaceutical industry.

역사Ranitidine was first prepared in England as AH19065 by John Bradshaw in the summer of 1977 in the Ware research laboratories of Allen and Hanburys, part of the former Glaxo organisation.Glaxo refined the model further, by replacing the imidazole ring of cimetidine with a furan ring with a nitrogen-containing substituent, and in doing so developed ranitidine. Ranitidine was found to have a far-improved tolerability profile (i.e. fewer adverse drug reactions), longer-lasting action, and 10 times the activity of cimetidine. Ranitidine was introduced in 1981, and was the world's biggest-selling prescription drug by 1987. Subsequently, it was largely superseded by the more effective proton-pump inhibitor (PPI) class of drugs, with omeprazole becoming the biggest-selling drug for many years.In September 2019, the probable carcinogen N-nitrosodimethylamine (NDMA) was discovered in ranitidine products from a number of manufacturers, resulting in recalls; in April 2020, it was withdrawn from the United States market and suspended in Europe and Australia. In 2024, ranitidine was re-approved for sale in Australia after the local sponsor of Zantac changed suppliers and tablet formulation. The new formulation was demonstrated to be stable throughout its shelf life and that nitrosamines are controlled within internationally established acceptable intake limits applied to the maximum daily dose.

용도Ranitidine (cas# 66357-35-5) was used as a standard for testing the therapeutic effect of brown propolis extract against aspirin and ethanol- induced gastric ulcers.

일반 설명Ranitidine, N-[2-[[[5-(dimethylamino)methyl]-2-furanyl]methyl]thiol] ethyl]-N'-methyl-2-nitro-l,1-ethenediamine (Zantac), is a white solid, which inits hydrochloride salt form is highly soluble in water. It is anaminoalkyl furan derivative with pKa values of 2.7 (sidechain) and 8.2 (dimethylamino). Ranitidine is more potentthan cimetidine, but less potent than famotidine. Likeother H2-antagonists, it does not appear to bind to otherreceptors.Bioavailability of an oral dose of ranitidine is about 50%and is not significantly affected by the presence of food.Some antacids may reduce ranitidine absorption and shouldnot be taken within 1 hour of administration of this drug. Theplasma half-life of the drug is 2 to 3 hours, and it is excretedalong with its metabolites in the urine. Three metabolites, ranitidineN-oxide, ranitidine S-oxide, and desmethyl ranitidine,have been identified. Ranitidine is only a weak inhibitor ofthe hepatic cytochrome isozymes, and recommended doses ofthe drug do not appear to inhibit the metabolism of otherdrugs. However, there have been isolated reports of drug interactions(warfarin, triazolam) that suggest that ranitidinemay affect the bioavailability of certain drugs by someunidentified mechanism, perhaps by pH-dependent effect onabsorption or a change in volume of distribution.In addition to being available in various dosage forms asthe hydrochloride salt, ranitidine is also available as a bismuthcitrate salt for use with the macrolide antibiotic clarithromycinin treating patients with an active duodenalulcer associated with H. pylori infection. Eradication of H.pylori reduces the risk of duodenal ulcer recurrence.

상·하류 제품 정보

상류 원료

니트로에틸렌황화디메틸L-시스테인퍼퓨릴 알코올메틸이소부틸케톤2,2'-티오비스에틸아민N,N-디메틸-2-푸르푸릴아민2-(Nitromethylene)thiazolidineN-Methyl-1-(methylthio)-2-nitroethylen-1-amine5-[(디메틸아미노)메틸]-2-푸란메탄올1,1-dichloro-2-nitroethene5-[[(2-아미노에틸)티오]메틸]-N,N-디메틸-2-푸르푸릴아민1.4-다이옥세인2-멜캅토에틸아민 수화염화물

관련 반응

67건
반응 기록 만들기
HRID 24285 반응식
HRID 24285반응물로
HRID 24286 반응식
HRID 24286반응물로
HRID 53909 반응식
HRID 53909반응물로
HRID 53910 반응식
HRID 53910반응물로
HRID 53911 반응식
HRID 53911반응물로
HRID 53912 반응식
HRID 53912반응물로
HRID 53913 반응식
HRID 53913반응물로
HRID 65761 반응식
HRID 65761생성물로
이전1 / 9 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트